22157.jpg
BRCA Tests Market Regulatory, Reimbursement and Forecasts to 2033
January 09, 2024 11:03 ET | Research and Markets
Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "BRCA Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering....
finacialnews-logo-final-01 (2).png
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024 10:25 ET | FN Media Group LLC
PALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled "Aging in the United States," published by the Population Reference Bureau, "the...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
January 08, 2024 08:12 ET | Olema Oncology
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 16:01 ET | Olema Oncology
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
22157.jpg
Breast Cancer Drugs Global Market Report 2024, Featuring Profiles of Key Players Novartis, AstraZeneca, Eli Lilly, Biocon, Merck and MacroGenics
December 14, 2023 11:03 ET | Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.The breast cancer drugs market size is set to to...
Future Market Insights.png
Europe Breast and Prostate Cancer Diagnostics Industry is estimated to reach US$ 5,030.1 Million by 2033 Amid Growing Research on Biomarkers | FMI Study
December 11, 2023 05:30 ET | Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Europe breast and prostate cancer diagnostics industry is estimated to reach US$ 4,041.5 million in 2023 and US$ 5,030.1 million by 2033. Over the...
Onconova Logo BLUE.jpg
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
December 08, 2023 16:05 ET | Onconova Therapeutics, Inc.
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Study Finds Opto-Acoustic Imaging During Neoadjuvant Therapy Correlates to Pathologic Response
Study Finds Opto-Acoustic Imaging During Neoadjuvant Therapy Correlates to Pathologic Response
December 08, 2023 14:00 ET | Seno Medical
San Antonio, Texas, Dec. 08, 2023 (GLOBE NEWSWIRE) -- A limited feasibility study presented at this year’s San Antonio Breast Cancer Symposium (SABCS) found that Seno Medical’s Imagio® Breast...
Celcuity+Logo.jpg
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
December 06, 2023 08:30 ET | Celcuity Inc.
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from...
arvinas_logoART_lg.jpg
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
December 05, 2023 22:52 ET | Arvinas Inc.
NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...